Gujarat Kidney And Super Speciality Limited (GKSL) — Financial Results

Investor Takeaways

Revenue increased by [amount not verified] YoY

Net profit rose by [amount context mismatch] Cr YoY

EBITDA grew by [amount not verified] YoY

⚠️ No specific risks identified in this filing

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	[amount not verified]	[amount not verified]
Net Profit	[amount not verified]	[amount context mismatch] Cr
EBITDA	[amount not verified]	[amount not verified]
EPS	[amount not verified]
OPM	11.5%

What Changed

The company demonstrated consistent profitability growth in the latest filing, with revenue, net profit, and EBITDA all showing positive year-on-year increases. Revenue reached [amount not verified], up [amount not verified] from the previous year, while net profit rose to [amount not verified], reflecting a ₹1.8 Cr improvement. EBITDA also increased to [amount not verified], up [amount not verified] YoY, indicating improved operational efficiency. The company maintained a stable operating profit margin of 11.5%, suggesting disciplined cost management. These figures reflect a steady upward trajectory in core financial performance without any reported declines in key metrics.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Gujarat Kidney And Super Speciality Limited (GKSL)	Not available	Not available	Not available	₹1,081.89
Sun Pharmaceutical Industries Limited (SUNPHARMA)	41.28	15.11%	20.34%	₹4,50,643.09
Divi's Laboratories Limited (DIVISLAB)	72.41	16.56%	22.09%	₹1,79,470.03
Torrent Pharmaceuticals Limited (TORNTPHARM)	80.06	N/A	N/A	₹1,49,108.91

The company has a significantly lower market capitalization compared to major peers like Sun Pharmaceutical and Divi's Laboratories, which may indicate a smaller scale of operations. However, its P/E, ROE, and ROCE metrics are not available in the provided data, limiting direct comparative analysis on profitability and efficiency.